Keyphrases
Adverse Events
17%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
18%
Antitumor Activity
9%
Bevacizumab
12%
Bortezomib
9%
Breast Cancer
40%
Brentuximab Vedotin
18%
Cancer Treatment
9%
Cancer Types
9%
Carboplatin
14%
Cetuximab
9%
Chemotherapy
50%
Chronic Lymphocytic Leukemia
10%
Circulating Tumor DNA (ctDNA)
12%
Cisplatin
16%
Clinical Outcomes
15%
Clinical Trials
28%
Colorectal Cancer
14%
Colorectal Liver Metastases
9%
Complete Response
16%
Confidence Interval
39%
Cyclophosphamide
12%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Disease Progression
11%
Docetaxel
15%
Dose Escalation
9%
Doxorubicin
20%
Etoposide
9%
Follicular Lymphoma
19%
Gemcitabine
16%
Glioblastoma
11%
Hazard Ratio
21%
Head-and-neck Cancer
9%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
12%
High Risk
11%
Hodgkin Lymphoma
14%
Immune Checkpoint Inhibitors
13%
In Cancer
18%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Lung Cancer
23%
Lymphoma
15%
Malignancy
9%
Mantle Cell Lymphoma
22%
Maximum Tolerated Dose
10%
Median Overall Survival
14%
Median Progression-free Survival
13%
Melanoma
12%
Metastasis
10%
Metastatic Breast Cancer
21%
Monotherapy
10%
Multiple Myeloma
9%
NCCN Guidelines
15%
Neoadjuvant
9%
Neutropenia
10%
Newly Diagnosed
9%
Non-Hodgkin Lymphoma
14%
Non-small Cell Lung Cancer (NSCLC)
47%
Objective Response Rate
11%
Older Adults
13%
Older Patients
10%
Oncology
14%
Overall Response Rate
14%
Overall Survival
59%
Paclitaxel
12%
Pan-cancer Analysis
10%
Pancreatic Cancer
14%
Pancreatic Ductal Adenocarcinoma
12%
Partial Response
15%
Pembrolizumab
13%
Peripheral T-cell Lymphoma
10%
Phase I Study
12%
Phase II Study
49%
Phase II Trial
40%
Placebo
11%
Prednisone
10%
Previously Treated
12%
Programmed Death-ligand 1 (PD-L1)
15%
Progression-free Survival
41%
Radiation Therapy
18%
Radiotherapy
9%
Randomized Phase II Trial
12%
Relapsed or Refractory
31%
Resection
9%
Response Rate
11%
Rituximab
28%
Sarcoma
11%
Small Cell Lung Cancer
11%
Soft Tissue Sarcoma
10%
Solid Tumors
13%
Stable Disease
11%
Systemic Therapy
10%
T Cells
14%
Targeted Therapy
20%
Treatment Options
9%
Triple-negative Breast Cancer
16%
Tumor
69%
Tumor Cells
11%
Tumor Microenvironment
9%
United States
9%
Whole Genome
10%
Medicine and Dentistry
Adjuvant Chemotherapy
6%
Adverse Event
19%
Arm
18%
B Cell
8%
B-Cell Chronic Lymphocytic Leukemia
8%
B-Cell Lymphoma
7%
Bendamustine
6%
Bevacizumab
7%
Biological Marker
17%
Breast Cancer
60%
Brentuximab Vedotin
12%
Cancer
28%
Cancer Cell
10%
Cancer Therapy
9%
Carboplatin
8%
Cetuximab
6%
Chemoradiotherapy
9%
Circulating Tumor DNA
10%
Cisplatin
13%
Classical Hodgkin Lymphoma
8%
Clear Cell Renal Cell Carcinoma
7%
Clinical Trial
33%
Cohort Analysis
6%
Colorectal Carcinoma
11%
Colorectal Liver Metastasis
7%
Connective Tissue Cancer
14%
Cyclophosphamide
10%
Cytotoxic T-Cell
6%
Diagnosis
6%
Diffuse Large B-Cell Lymphoma
17%
Disease Exacerbation
6%
Disease Free Survival
6%
Diseases
67%
Doxorubicin
13%
Epidermal Growth Factor Receptor
8%
Etoposide
6%
Follicular Lymphoma
13%
Gemcitabine
9%
Glioblastoma
9%
Hazard Ratio
15%
Head and Neck Cancer
6%
Head and Neck Squamous Cell Carcinoma
8%
Health Care Cost
6%
Hematopoietic Cell
7%
Hodgkin's Lymphoma
19%
Hormone Therapy
9%
Human Immunodeficiency Virus
8%
Ibrutinib
6%
Immune Checkpoint Inhibitor
10%
Immunity
13%
Immunotherapy
26%
Lenalidomide
6%
Lung Cancer
27%
Malignant Neoplasm
64%
Mantle Cell Lymphoma
19%
Melanoma
16%
Metastatic Breast Cancer
13%
Metastatic Carcinoma
25%
Monotherapy
6%
Multiple Myeloma
8%
Neoadjuvant Chemotherapy
7%
Neoplasm
100%
Nivolumab
6%
Non Small Cell Lung Cancer
42%
Non-Hodgkin Lymphoma
18%
Oncology
30%
Overall Survival
60%
Paclitaxel
11%
Pancreas Adenocarcinoma
10%
Pancreas Cancer
11%
Pembrolizumab
11%
Peripheral T-Cell Lymphoma
10%
Phase II Trials
12%
Placebo
10%
Positron Emission Tomography
10%
Primary Tumor
6%
Prognostic Factor
6%
Progression Free Survival
40%
Prostate Cancer
11%
Quality of Life
9%
Radiation Therapy
27%
Rectum Cancer
6%
Recurrent Disease
18%
Rituximab
25%
Small Cell Lung Cancer
11%
Soft Tissue Sarcoma
10%
Solid Malignant Neoplasm
10%
Squamous Cell Carcinoma
7%
Surgery
18%
Survival Rate
7%
Systematic Review
7%
Systemic Therapy
11%
T Cell
16%
Targeted Therapy
20%
Transitional Cell Carcinoma
6%
Transplantation
13%
Triple Negative Breast Cancer
12%
Tumor Cell
8%
Tumor Progression
10%
Vincristine
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
27%
Anemia
5%
Antitumor Activity
8%
B Cell Lymphoma
5%
Bendamustine
9%
Bevacizumab
10%
Biological Marker
14%
Bortezomib
8%
Breast Cancer
32%
Brentuximab Vedotin
9%
Carboplatin
14%
Carcinogenesis
5%
Castration Resistant Prostate Cancer
5%
Cetuximab
9%
Chemoradiation Therapy
11%
Chemotherapy
65%
Chronic Lymphatic Leukemia
8%
Circulating Tumor DNA
5%
Cisplatin
15%
Clinical Trial
28%
Colorectal Carcinoma
10%
Combination Therapy
5%
Connective Tissue Cancer
6%
Cyclophosphamide
14%
Diarrhea
7%
Diffuse Large B Cell Lymphoma
15%
Disease Exacerbation
8%
Disease Free Survival
5%
Diseases
58%
Docetaxel
14%
Doxorubicin
21%
Endocrine Therapy
5%
Epidermal Growth Factor Receptor
11%
Erlotinib
5%
Estrogen Receptor
5%
Etoposide
9%
Everolimus
5%
Follicular Lymphoma
16%
Gemcitabine
13%
Glioblastoma
10%
Head and Neck Cancer
5%
Head and Neck Squamous Cell Carcinoma
8%
Hodgkin Disease
12%
Ibrutinib
5%
Immune Checkpoint Inhibitor
7%
Immunotherapy
15%
Irinotecan
5%
Lenalidomide
7%
Leukemia
7%
Liver Cell Carcinoma
5%
Lung Cancer
25%
Malignant Neoplasm
56%
Mantle Cell Lymphoma
16%
Maximum Tolerated Dose
9%
Melanoma
10%
Metastasis
10%
Metastatic Breast Cancer
17%
Methotrexate
5%
Monoclonal Antibody
5%
Monotherapy
9%
Multiple Myeloma
5%
Nausea
5%
Neoplasm
77%
Neutropenia
10%
Nivolumab
5%
Non Small Cell Lung Cancer
46%
Nonhodgkin Lymphoma
20%
Overall Survival
55%
Paclitaxel
21%
Palbociclib
5%
Pancreas Adenocarcinoma
8%
Pancreas Cancer
9%
Pembrolizumab
8%
Pemetrexed
6%
Peripheral T Cell Lymphoma
5%
Pharmacokinetics
10%
Phase I Trials
5%
Phase II Trials
19%
Phosphatidylinositol 3 Kinase
5%
Placebo
13%
Prednisone
8%
Progression Free Survival
46%
Prostate Cancer
14%
Receptor
6%
Recurrent Disease
12%
Remission
10%
Renal Cell Carcinoma
6%
Rituximab
31%
Small Cell Lung Cancer
13%
Soft Tissue Sarcoma
8%
Solid Malignant Neoplasm
18%
Squamous Cell Carcinoma
5%
Survival Rate
7%
Temozolomide
5%
Thrombocytopenia
6%
Tolerability
7%
Transitional Cell Carcinoma
6%
Triple Negative Breast Cancer
8%
Tumor Growth
8%
Vincristine
9%